Real‐World Data Analysis of Vascular and Lymphatic Adverse Events Associated With Antitumor Angiogenesis Drugs: A WHO‐VigiAccess Study

Antiangiogenic therapy plays a critical role in cancer treatment. This study analyzed vascular and lymphatic adverse events linked to four FDA‐approved agents—aflibercept, bevacizumab, olaratumab, and ramucirumab—using WHO‐VigiAccess data. Disproportionality analysis (ROR and PRR) identified drug‐specific risks, focusing on hypertension, hemorrhage, thrombosis, and flushing, to inform safer and personalized clinical use.